Sara Busacca

1.2k total citations
24 papers, 686 citations indexed

About

Sara Busacca is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Biotechnology. According to data from OpenAlex, Sara Busacca has authored 24 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 4 papers in Biotechnology. Recurrent topics in Sara Busacca's work include Occupational and environmental lung diseases (16 papers), Pleural and Pulmonary Diseases (5 papers) and Cancer Research and Treatments (4 papers). Sara Busacca is often cited by papers focused on Occupational and environmental lung diseases (16 papers), Pleural and Pulmonary Diseases (5 papers) and Cancer Research and Treatments (4 papers). Sara Busacca collaborates with scholars based in United Kingdom, United States and Ireland. Sara Busacca's co-authors include Giovanni Gaudino, Dean A. Fennell, Gabriela M. Almeida, Raquel T. Lima, M. Helena Vasconcelos, Dean A. Fennell, Loris De Cecco, Luciano Mutti, Marco A. Pierotti and Federico Comoglio and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Sara Busacca

21 papers receiving 677 citations

Peers

Sara Busacca

PRM

ONCOL

IMMUN

Sophie Couvé France

Jean-Philippe Cosse Belgium

Stefanie Kurtz Switzerland

Shinsuke Hashida Japan

Yifei Feng China

Choon‐Taek Lee South Korea

Corrina M.A. de Ridder Netherlands

Steffen Dietz Germany

Ramya Kumareswaran Canada

Linda Fabris United States

Sophie Couvé France

Sara Busacca

495 ×1.3

228 ×0.8

PRM

259 ×1.0

219 ×1.9

ONCOL

118 ×2.6

IMMUN

Citations per year, relative to Sara Busacca Sara Busacca (= 1×) peers Sophie Couvé

Countries citing papers authored by Sara Busacca

Since Specialization

Citations

This map shows the geographic impact of Sara Busacca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Busacca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Busacca more than expected).

Fields of papers citing papers by Sara Busacca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Busacca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Busacca. The network helps show where Sara Busacca may publish in the future.

Co-authorship network of co-authors of Sara Busacca

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Busacca. A scholar is included among the top collaborators of Sara Busacca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Busacca. Sara Busacca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ulahannan, Susanna V., Jason T. Henry, Kathleen N. Moore, et al.. (2025). Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors. Cancer Research. 85(8_Supplement_2). CT267–CT267.

Moore, Kathleen N., Manish R. Patel, Gerald S. Falchook, et al.. (2023). 680P First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors. Annals of Oncology. 34. S475–S476. 5 indexed citations

Busacca, Sara, Aarti Gaba, Michael Sheaff, et al.. (2022). BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. Oncogene. 42(8). 572–585. 12 indexed citations

Fennell, Dean A., J.F. Lester, Sarah Danson, et al.. (2022). Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. EClinicalMedicine. 48. 101432–101432. 17 indexed citations

Busacca, Sara, Qi Zhang, Annabel Sharkey, et al.. (2021). Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Scientific Reports. 11(1). 7434–7434. 5 indexed citations

Busacca, Sara, Laura O’Regan, Annabel Sharkey, et al.. (2020). BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Molecular Cancer Therapeutics. 20(2). 379–388. 13 indexed citations

Fennell, Dean A., Sarah Danson, Penella J. Woll, et al.. (2020). Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial. Clinical Cancer Research. 26(18). 4748–4755. 13 indexed citations

Fennell, Dean A., Sarah Danson, Martin Förster, et al.. (2018). MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma. Journal of Thoracic Oncology. 13(10). S397–S397. 2 indexed citations

Sharkey, Annabel, Luke Martinson, John Le Quesne, et al.. (2017). P3.03-005 Inhibition of PRMT5 is Synthetic Lethal in Mesotheliomas Harboring MTAP Loss. Journal of Thoracic Oncology. 12(1). S1346–S1346. 1 indexed citations

10.

Busacca, Sara, Ian Powley, David A. Proia, et al.. (2015). Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene. 35(12). 1483–1492. 24 indexed citations

11.

Richards, Mark W., Sara Busacca, Laura O’Regan, et al.. (2014). Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain. Proceedings of the National Academy of Sciences. 111(14). 5195–5200. 75 indexed citations

12.

Busacca, Sara, Astero Klabatsa, Ken Arthur, et al.. (2013). BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. PLoS ONE. 8(6). e65489–e65489. 13 indexed citations

13.

Barbone, Dario, Priscilla Cheung, Sara Busacca, et al.. (2012). Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression. PLoS ONE. 7(12). e52753–e52753. 29 indexed citations

14.

Fennell, Dean A., Clíona McDowell, Sara Busacca, et al.. (2012). Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 7(9). 1466–1470. 39 indexed citations

15.

Busacca, Sara, Nyree Crawford, Francis McCoy, et al.. (2012). Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death and Disease. 3(12). e449–e449. 1 indexed citations

16.

Blayney, Jaine K., Giovanni Luca Ceresoli, B. Castagneto, et al.. (2012). Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. European Journal of Cancer. 48(16). 2983–2992.

17.

Hurwitz, Jane, Emma Kerr, Caitriona Holohan, et al.. (2011). Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. European Journal of Cancer. 48(7). 1096–1107. 36 indexed citations

18.

Busacca, Sara, Michael Sheaff, Ken Arthur, et al.. (2011). BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma. The Journal of Pathology. 227(2). 200–208. 23 indexed citations

19.

Lima, Raquel T., Sara Busacca, Gabriela M. Almeida, et al.. (2010). MicroRNA regulation of core apoptosis pathways in cancer. European Journal of Cancer. 47(2). 163–174. 222 indexed citations

20.

Busacca, Sara, Serena Germano, Loris De Cecco, et al.. (2009). MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. American Journal of Respiratory Cell and Molecular Biology. 42(3). 312–319. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact